An investigational transdermal cannabidiol gel was well-tolerated and consistently effective for adults with focal epilepsy. NEW ORLEANS — Treatment with ZYN002, an investigational transdermal ...
Please provide your email address to receive an email when new articles are posted on . Focal cortex stimulation with an implantable device reduced seizure activity in more than 50% of participants at ...
Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...
The US Food and Drug Administration (FDA) has approved cenobamate (Xcopri, SK Life Science) for the treatment of partial-onset seizures in adult patients with epilepsy. Today's approval was based on ...
Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...
LONDON, June 05, 2025--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of ...
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that its lead product candidate, NRTX-1001, ...
A pair of studies will offer insights into the therapeutic effects of specialized diets in adults with epilepsy. Researchers have long known that dietary therapy, in conjunction with a regimen of anti ...
Post-hoc analysis from open-label Phase 3 study shows treatment with cenobamate led to a reduction of concomitant anti-seizure medications (ASMs) while maintaining ≥50% and 100% seizure reduction ...
BOSTON — Preliminary results from a meta-analysis have shown that antiepileptic drugs (AEDs) approved for adults with primary generalized tonic-clonic (PGTC) seizures are also effective in children ...
Researchers have discovered that light from an ultraviolet diode (UV LED) reduced "seizure-like" activity in a rat epilepsy model. Results of this study have considerable potential in treating focal ...
(Reuters) - Marinus Pharmaceuticals Inc said it plans to stop development of its treatment for drug-resistant focal onset seizures in adults after it failed a late-stage trial, sending the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback